Source: Barron's
Gilead's (GILD) revenue has been uneven for several quarters. The company's top line has gone through fits and starts, and I am not sure if it will end any time soon. Q3 2019 revenue of $5.6 billion fell 1% Q/Q. This followed a high-single-digit percentage increase in Q2. It is difficult to recommend the stock until the company generates consistent revenue growth. Heading into Q3, HIV revenue was growing in the high-single-digit percentage range, and HCV was showing life due to claw back reserves pursuant to sales from prior periods.
In